AriBio Co., Ltd. and Fujirebio Diagnostics, Inc. Announce Strategic Partnership to Advance Biomarker Development for Alzheimer’s Disease and Neurodegeneration
8.3.2023 15:30:00 EET | Business Wire | Press release
Fujirebio Holdings Inc., its wholly-owned subsidiary Fujirebio Diagnostics, Inc., and AriBio Co., Ltd. announced a strategic partnership to advance the development of biomarkers for Alzheimer’s disease and other neurodegenerative conditions. The agreement provides Fujirebio access to clinical samples and data collected as part of the ongoing Phase 3 Alzheimer’s disease study launched by AriBio in Dec. 2022.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20230308005122/en/
AriBio completed a Phase 2 study in 2021 in mild to moderate Alzheimer’s disease patients with their lead compound AR1001, a PDE5 inhibitor with preclinical efficacy shown to inhibit neuron apoptosis, promote neurogenesis, increase neuroplasticity, and stimulate autophagy activity to remove toxic proteins. The Phase 3 study in patients with early Alzheimer’s disease, AR1001-ADP3-US01, has been launched in the United States and plans to expand to other countries in 2023.
Fujirebio, a trusted partner for high-quality IVD testing solutions and a pioneer in neurodegenerative disease diagnostics is committed to the advancement of biomarkers to improve diagnosis of Alzheimer’s disease. Fujirebio was the first company to develop and market cerebrospinal fluid (CSF) biomarkers for Alzheimer’s disease testing and the first to receive FDA authorization in 2022 for its Lumipulse® G β-Amyloid Ratio (1-42/ 1-40) test. Fujirebio continues to make advances in the field to provide fully automated blood-based tests for Alzheimer’s disease and other neurological disorders.
“AriBio is committed to advancing not just the treatment options for patients with Alzheimer’s disease and their families, but also the development of better diagnostics and improved characterization of this devastating disease. This initial partnership with Fujirebio is the first of several we plan to launch in the next few years as we expand our clinical programs into other areas of neurodegeneration. Fujirebio is an ideal partner for us and reflects our commitment to advancements in this space. We look forward to working closely with Fujirebio to improve the detection of Alzheimer’s disease and other neurodegenerative diseases with their pioneering assays,” commented James Rock, President of AriBio Co., Ltd US Office.
“Fujirebio continues to lead the industry in the development of high quality, functional tests to improve clinicians’ ability to detect and diagnose a variety of neurodegenerative conditions. We continue to partner with organizations and clinical experts across the world to develop new pathways for earlier, easier, and more complete neurodegenerative diagnostic tools,” stated Monte Wiltse, President and CEO of Fujirebio Diagnostics, Inc.
About AR1001-ADP3-US01
AR1001-ADP3-US01 (NCT05531526) is Phase 3 Double-blind, Randomized, Placebo-controlled, Multi-center Trial to Evaluate the Efficacy and Safety of AR1001 over 52 Weeks in Participants with Early Alzheimer’s Disease. The study aims to assess the efficacy and safety of AR1001 in slowing the progression of Alzheimer's disease through various cognitive and functional assessments. The details of the clinical trial are available at ClinicalTrials.gov.
About AriBio
AriBio Co., Ltd. is a biopharmaceutical company based in South Korea with offices in the United States. The company focuses on the development of novel therapies for neurodegenerative diseases including Alzheimer’s disease. The company continues to expand its partnerships to accelerate best-in-class treatment options and further advancements in the field of medicine.
About Fujirebio
Fujirebio Diagnostics, Inc., a wholly owned subsidiary of H.U. Group Holdings, Inc. and Fujirebio Holdings, Inc., is a premier diagnostics company and the industry leader in cancer biomarker tests. Fujirebio Diagnostics specializes in the contract development and manufacturing for the diagnostics industry leaders and market development of novel in-vitro diagnostic products for the management of human disease states. For more information about Fujirebio Diagnostics, please call +1 610-240-3800 or visit us at www.fujirebio.com. H.U. Group Holdings, Inc. (formerly known as Miraca Holdings Inc.) is a listed company on the Tokyo Stock Exchange – TYO: 4544.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20230308005122/en/
Contact information
James Rock – AriBio
jimrock@aribiousa.com
Chris Dague – Fujirebio
chris.dague@fujirebio-us.com
About Business Wire
For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
LTM and Uniphore Partner to Scale Domain-Specific AI Across Core Business Processes5.5.2026 16:15:00 EEST | Press release
Uniphore, the Business AI Company, and LTM, the Business Creativity partner to the world's largest enterprises, today announced a strategic partnership focused on the joint development of industry- and domain-specific AI solutions that combine small language models (SLMs), AI agents, and deep domain expertise. As AI adoption matures, enterprises are shifting to smaller, purpose‑built models and agents for greater precision and control. The partnership brings this approach to core business processes with governance, security, and compliance by design. Uniphore’s Business AI Cloud will power LTM’s BlueVerse™ ecosystem and global delivery, unifying enterprise data, models, and AI agents on a secure, sovereign platform. LTM will drive industry expertise, client implementation, and AI‑led transformation, while Uniphore provides the foundation for building and fine‑tuning domain‑specific SLMs. The partnership will initially focus on banking, financial services, and insurance (BFSI), manufact
QuantWare Raises $178 Million to Build World’s Most Powerful Quantum Processors at an Industrial Scale5.5.2026 16:00:00 EEST | Press release
QuantWare, the leading industrial quantum processor company, today announced a $178 million (€152 million) Series B equity funding round following the announcement of VIO-40K™, a quantum processor architecture for 10,000 qubits, 100x larger than the state of the art today. The company is building KiloFab, the world’s largest dedicated quantum open architecture fab, increasing the company’s production capacity by 20x to meet strong global customer demand. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260505645970/en/ QuantWare co-founders Matthijs Rijlaarsdam (CEO) and Alessandro Bruno (CTO), pictured outside of QuantWare's KiloFab facility in Delft, Netherlands. QuantWare is the only company that designs, fabricates, and integrates modular quantum processors on an open architecture at an industrial scale. Its proprietary VIO™ technology — a modular Quantum Processor Architecture — allows the creation of the world’s most pow
Tacton, Award-Winning Innovation Leader, Launches AI Product Modeling Assistant to Accelerate CPQ Implementation and Eliminate Bottlenecks5.5.2026 16:00:00 EEST | Press release
Tacton, a global leader in Configure, Price, Quote (CPQ) solutions for manufacturers of complex products, today announced the launch of AI Product Modeling Assistant, a new capability designed to dramatically accelerate product modeling and remove one of the most persistent barriers to CPQ success. Tacton’s AI Modeling Assistant is part of a core innovation to its CPQ platform, earning a Gold win in the 24th Annual American Business Awards for Most Innovative Tech Company of the Year. For manufacturers with highly configurable products, product modeling is often the longest and most resource-intensive phase of CPQ implementation. It determines how quickly products can be brought to market, how much of the portfolio is available at launch, and ultimately how fast organizations realize value from their CPQ investment. At the same time, many manufacturers face increasing pressure from limited modeling expertise, workforce shortages, and the retirement of experienced engineers, making it e
Tourism Surges in Oulu as European Capital of Culture Year Drives Record Visitor Numbers and Major Exhibitions5.5.2026 15:23:00 EEST | Press release
The year has started strongly in Oulu, Finland, with tourism and cultural attendance rising across sectors. In January–February, total overnight stays increased by more than 20%, while February alone saw a 32% increase, reaching 78,400 stays. International tourism grew by over 40%. At the same time, the opening festival in January attracted around 250,000 visits, highlighting strong interest among both residents and visitors and signalling a promising year for the city’s tourism sector. “The start of the year has clearly shown the power of culture in strengthening tourism and regional vitality,” says Oulu2026 Programme Director Samu Forsblom. “With hundreds of cultural operators across all 39 municipalities involved, this is a unique year to visit our region in northern Finland.” A year of major exhibitions across the city Oulu’s exhibition programme extends beyond traditional museum spaces. Art appears in unexpected places such as a shopping centre, the city hall, a cathedral and in n
Bracco Launches BubbleGen™ Early Access Program for Microbubble-Based Cell Selection and Activation at ISCT5.5.2026 15:00:00 EEST | Press release
Bracco Imaging,a global pharmaceutical company that develops, manufactures, and markets innovative healthcare solutions, unveiled its Early Access Program today to enable cell therapy developers to evaluate the company’s new BubbleGen™ technology for cell therapy. Bracco’s team will be showcasing BubbleGen, which is designed to support a range of streamlined cell therapy manufacturing processes, at the International Society for Cell & Gene Therapy (ISCT) 2026 conference held this week in Dublin, Ireland. Through the BubbleGen evaluation kit, academic and industry researchers can explore a new approach to cell separation. The technology uses buoyant microbubbles to isolate specific cells, offering an alternative to traditional magnetic bead-based methods. The initial test case supports CD3+ T cell selection and activation in a format commonly used in commercial CAR T-cell therapies, and the platform is designed to extend beyond standard workflows. Researchers can adapt the system to iso
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom